# Adjuvant Chemotherapy in Patients With Clinical Stage III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy

> **NCT03415763** · PHASE3 · UNKNOWN · sponsor: **LI XIN-XIANG** · enrollment: 764 (estimated)

## Conditions studied

- Rectal Neoplasms

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** mFOLFOX6 or CAPOX

## Key facts

- **NCT ID:** NCT03415763
- **Lead sponsor:** LI XIN-XIANG
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-05
- **Primary completion:** 2020-12
- **Final completion:** 2025-12
- **Target enrollment:** 764 (ESTIMATED)
- **Last updated:** 2018-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03415763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03415763, "Adjuvant Chemotherapy in Patients With Clinical Stage III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03415763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*